API
< Back to situations

This situation has concluded

It was preserved as a record on August 31; the timeline below shows how it unfolded, with sources. Get the briefing to follow the top situations still developing: three emails a week, sourced and in order.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 11 sources · 4 days · First seen · Last updated

EU approval of XFG‑adapted COVID‑19 vaccine

Overview

In late July 2026, the European Medicines Agency (EMA) and the U.S. FDA recommended that COVID‑19 vaccines for the 2026‑27 respiratory‑illness season target the XFG (Stratus) variant, which made up about 74 % of sequenced infections worldwide in October 2025. The European Commission responded by granting marketing authorisation for Pfizer‑BioNTech’s monovalent XFG‑adapted vaccine across all 27 EU Member States and the EEA members Iceland, Liechtenstein and Norway.

Production of the updated Comirnaty formulation began at risk to secure supply for the autumn‑winter campaign. The vaccine is authorised for individuals six months and older. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion based on clinical, pre‑clinical and real‑world data supplied by the manufacturers, and shipments were slated to start shortly after approval.

The authorisations aim to provide the best protection against the predominant XFG strain, continuing the EU’s effort to mitigate COVID‑19 mortality, which prior global vaccination campaigns have estimated to have prevented roughly 14.4 million deaths across 185 countries.

Entities

European Medicines Agency · XFG variant · European Commission · European Commission (EC) · Food and Drug Administration

Timeline

  1. [HEALTH] 7 sources
    EU approves updated Pfizer‑BioNTech Comirnaty vaccine targeting XFG variant

    The EU Commission has approved the 2026‑27 Pfizer‑BioNTech Comirnaty vaccine updated for the XFG variant, authorising use from six months old across the EU and EEA with production and shipments underway for the

  2. [HEALTH] 4 sources
    EU Authorises Pfizer‑BioNTech XFG‑Adapted COVID‑19 Vaccine for 2026‑27 Season

    EMA and FDA recommend the 2026‑27 COVID‑19 vaccine target the XFG variant; the EU has authorised Pfizer‑BioNTech’s XFG‑adapted shot, with production already underway.

Sources

codirp.it · diariomomento.com · doctor33.it · donne.notizie.it · expresspharma.in · infomeddnews.com · lecodellitorale.it · quotidianodibari.it · quotidianodifoggia.it · tecnologia-informatica.com · unmondoditaliani.com